Actively Recruiting
Open-Label Phase 1 Study to Assess Safety, Tolerability, and Immune Effects of Intravenous HBM7020 in Healthy Adults and Adults With Autoimmune Diseases
Led by Otsuka Pharmaceutical Development & Commercialization, Inc. · Updated on 2026-10-13
63
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, how the body absorbs and processes HBM7020, and its immune effects in healthy adults and adults with certain autoimmune diseases. The autoimmune conditions included are systemic lupus erythematosus, systemic sclerosis, Sjgrens disease, and rheumatoid arthritis. This first-in-human phase 1 clinical trial aims to evaluate how HBM7020 behaves in the body and its safety profile. Participants will receive HBM7020 through intravenous infusion in a stepwise dose increase during the first part of the trial. In the second part, some participants may have the option to receive retreatment with HBM7020 if they qualify. The study includes healthy adults at low doses initially, followed by patients with active moderate to severe autoimmune disease who are on stable background therapy. During the trial, participants will be monitored up to 48 weeks for adverse events and changes in vital signs and physical exams. Blood samples will be collected to measure immune markers and drug levels. Researchers will also assess the presence of anti-drug antibodies and inflammatory markers to understand the drugs effects. Participants will have regular assessments to evaluate safety and immune response throughout the study.
CONDITIONS
Brief Title
A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body
Research Team
O
Otsuka Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here